KEI Comments on Proposed Exclusive License to Connectyx for Degenerative Retinal Disease Treatment

On November 6, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the, “Prospective Grant of an Exclusive Patent License: Development of a Direct Ocular Administered Formulation of Metformin for Use in Therapeutic Treatment… Continue Reading

KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx

On Friday September 11, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate… Continue Reading